Marketing-authorisation holder · United States
Pfizer Inc.
209 medicines in 1 country, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
209 medicines in 1 country, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 209
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ABRILADA10mg/0.2ml | 20mg/0.4ml | 40mg/0.8ml · Injectable | Adalimumab | United States | Marketed | 2019 |
| Abrilada40mg/0.8ml · Injection | Adalimumab | United States | Marketed | 2019 |
| Abrilada10mg/0.2ml · Injection | Adalimumab | United States | Not marketed | 2019 |
| Abrysvo120ug · Injection | Respiratory syncytial virus vaccines | United States | Marketed | 2023 |
| ACCUPRIL10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 40MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 5MG BASE * · Tablet | Quinapril | United States | Not marketed | 1991 |
| ACCURETIC12.5MG; 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 12.5MG; 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 25MG; 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness · Tablet | Hydrochlorothiazide, Quinapril | United States | Not marketed | 1999 |
| ADRIAMYCIN PFS200mg/100ml | 2mg/ml · Injectable | Doxorubicin | United States | Not marketed | 1991 |
| ALDACTAZIDE25mg; 25mg | 50mg; 50mg · Tablet | Hydrochlorothiazide, Spironolactone | United States | Marketed | 1961 |
| ALDACTONE100mg | 25mg | 50mg · Tablet | Spironolactone | United States | Marketed | 1960 |
| AROMASIN25mg · Tablet | Exemestane | United States | Marketed | 1999 |
| ARTHROTEC50mg; 0.2mg | 75mg; 0.2mg · Tablet, delayed release | Diclofenac, Misoprostol | United States | Marketed | 1997 |
| ATARAX100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 50MG **Federal Register · Tablet | Hydroxyzine | United States | Not marketed | 1956 |
| AZULFIDINE500mg · Tablet | Sulfasalazine | United States | Marketed | 1950 |
| AZULFIDINE EN-TABS500mg · Tablet, delayed release | Sulfasalazine | United States | Marketed | 1950 |
| CALAN120MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 160MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 80MG **Federal Register · Tablet | Verapamil | United States | Not marketed | 1984 |
| CALAN SR120MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 180MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 240MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet, extended release | Verapamil | United States | Not marketed | 1986 |
| CAMPTOSAR100mg/5ml (20mg/ml) | 300mg/15ml (20mg/ml) | 40mg/2ml (20mg/ml) · Injectable | Irinotecan | United States | Marketed | 1996 |
| CAVERJECT0.005mg/ml | 0.005mg/vial | 0.01mg/ml | 0.01mg/vial | 0.02mg/ml | 0.02mg/vial | 0.04mg/vial · Injectable | Alprostadil | United States | Marketed | 1995 |
| CAVERJECT IMPULSE0.01mg/vial | 0.02mg/vial · Injectable | Alprostadil | United States | Marketed | 2002 |
| CEFOBID10gm base/vial | 1gm base/vial | 2gm base/vial · Injectable | Cefoperazone | United States | Not marketed | 1982 |
| CEFOBID IN PLASTIC CONTAINER20mg base/ml | 40mg base/ml · Injectable | Cefoperazone | United States | Not marketed | 1986 |
| CIBINQO100mg | 200mg | 50mg · Tablet | Abrocitinib | United States | Marketed | 2022 |
| CLEOCIN100mg · Suppository | Clindamycin | United States | Marketed | 1999 |
| CLEOCIN75MG BASE/5ML | 75MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · For solution | Clindamycin palmitate | United States | Marketed | 1986 |
| CLEOCIN1% base · Swab | Clindamycin | United States | Not marketed | 1980 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 209 | 208 | 1 | CompaniesAll medicines |
Also in the registers of Brazil
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
GLEIF; exact source URLs/locators, version status and retrieval dates. Normalized by Prognia; no official endorsement.
Licence: CC0
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.